Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
43.36
+1.16 (2.75%)
At close: Nov 26, 2025, 4:00 PM EST
43.98
+0.62 (1.43%)
After-hours: Nov 26, 2025, 7:08 PM EST

Mineralys Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
31.9223.8214.35.232.420.53
Research & Development
152.18168.5870.3626.2516.312.41
Operating Expenses
184.09192.484.6631.4818.732.94
Operating Income
-184.09-192.4-84.66-31.48-18.73-2.94
Interest Expense
-----0.03-0.12
Interest & Investment Income
12.7214.5912.761.68--
Other Non Operating Income (Expenses)
0.010.01000-0.37
EBT Excluding Unusual Items
-171.36-177.81-71.9-29.8-18.75-3.43
Other Unusual Items
-----0.66-
Pretax Income
-171.36-177.81-71.9-29.8-19.41-3.43
Net Income
-171.36-177.81-71.9-29.8-19.41-3.43
Net Income to Common
-171.36-177.81-71.9-29.8-19.41-3.43
Shares Outstanding (Basic)
604936555
Shares Outstanding (Diluted)
604936555
Shares Change (YoY)
29.86%34.13%600.33%3.67%7.64%-
EPS (Basic)
-2.86-3.66-1.99-5.77-3.89-0.74
EPS (Diluted)
-2.86-3.66-1.99-5.77-3.89-0.74
Free Cash Flow
-171.37-166.41-81.17-29.22-14.56-2.46
Free Cash Flow Per Share
-2.86-3.43-2.24-5.66-2.92-0.53
EBITDA
-184.03-192.36----
D&A For EBITDA
0.060.04----
EBIT
-184.09-192.4-84.66-31.48-18.73-2.94
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q